Tag: M.W:100-200

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.14162-94-8,4-Chloro-2,2′-bipyridine,as a common compound, the synthetic route is as follows.

0.303 g (9.45¡Á10-4 mol) of compound 1 and 2 g of KOH were stirred in 10 mL of DMSO for 10 min. 0.645 g (3.38¡Á10-3) of 4-chloro-2,2′-bipyridine was added. The reaction mixture was continuously stirred under argon at 50 C. for 22 hrs. After reaction, the mixture was poured into 30 mL of water. Extraction with 100 mL of CH2Cl2 was tried when the solution was highly alkaline but it was found difficult to separate the two phases. After evaporation of CH2Cl2, the oil was purified by chromatography (silica gel treated with 20% triethylamine in hexane, elution 5-10% methanol in CH2Cl2 and pure methanol) and vacuum dried to afford a sticky transparent product. This was dissolved in methanol and precipitated in acidified water to yield 52 mg of white powder. The remaining water phase was adjusted to pH=8 with NH3H2O. The solution was further extracted with CH2Cl2 until no more bipyridine derivatives could be detected by TLC. After evaporation of CH2Cl2, the oil was purified by chromatography (silica gel treated with 20% triethylamine in hexane, elution 5-10% methanol in CH2Cl2, and pure methanol), vacuum dried and precipitated in acidified water to yield 223 mg of product. The yield for the combined product is 37%. 1H NMR (400 MHz, CDCl3) delta 8.63 (d, 3 H), 8.45 (d, 3H), 8.32 (d, 3 H), 7.4-8.2 (b, 4 H, NH4), 7.97 (d, 3 H), 7.76 (t,3 H), 7.26 (t, 3 H), 6.84 (dd, 3 H), 4.39 (s, 6 H, 3 CH2O), 3.72 (s, 2 H, CH2O), 3.38 (t,2 H, OCH2), 2.20 (t, 2 H, CH2), 1.53 (q, 2 H, CH2), 1.45. (q, 2 H, CH2), 1.0-1.2 (b, 12 H, 6 CH2)., 14162-94-8

14162-94-8 4-Chloro-2,2′-bipyridine 15207243, acatalyst-ligand compound, is more and more widely used in various fields.

Reference£º
Patent; Zhou, Ming; Roovers, Jacques; US2005/59834; (2005); A1;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

62937-45-5,62937-45-5, D-Prolinamide is a catalyst-ligand compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

General procedure: A stirred suspension of 2-chloro-N-(1-methyl-1H-imidazol-4-yl)furo[3,2-d]pyrimidin-4-amine (1b) (100 mg, 0.40 mmol), (S)-pyrrolidin-2-ylmethanol (122 mg, 1.20 mmol) in N-Methyl-2-pyrrolidinone (1 mL) was subjected to microwave irradiation at 150 C for 2 h. The reaction mixture was diluted with ethyl acetate (50 mL), washed with brine (2 x 20 mL), dried, filtered and concentrated in vacuum. The crude residue was purified by combiflash (silica gel, 12 g, eluting with chloroform/CMA-80) to afford (S)-(1-(4-((1-methyl-1H-imidazol-4-yl)amino)furo[3,2-d]pyrimidin-2-yl)pyrrolidin-2-yl)methanol (2a) (43 mg, 34 % yield) as a light yellow solid; NMR (300 MHz, DMSO-i) delta 9.90 (s, 1H, D20 exchangeable), 8.00 (d, J = 2.1 Hz, 1H), 7.44 (s, 1H), 7.42 (d, J = 1.4 Hz, 1H), 6.71 (d, J = 2.1 Hz, 1H), 4.94 (s, 1H, D2O exchangeable), 4.13 (s, 1H), 3.83 – 3.69 (m, 1H), 3.64 (s, 3H), 3.62 – 3.49 (m, 1H), 3.48 – 3.23 (m, 2H), 2.07 – 1.83 (m, 4H); MS (ES+): 315.4 (M+l), 337.5 (M+Na), (ES-): 313.4 (M- 1). HPLC purity: 98.70%.

62937-45-5 D-Prolinamide 447554, acatalyst-ligand compound, is more and more widely used in various fields.

Reference£º
Patent; BIOCRYST PHARMACEUTICALS, INC.; KOTIAN, Pravin, L.; BABU, Yarlagadda, S.; KUMAR, V., Satish; ZHANG, Weihe; LU, Peng-Cheng; RAMAN, Krishnan; (747 pag.)WO2018/232094; (2018); A1;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.62937-45-5,D-Prolinamide,as a common compound, the synthetic route is as follows.

62937-45-5, A solution of 5-(4-chlorophenyl)-2-{ [l-(4-chloropyridin-3-yl) H-l,2,4-triazol-3-yl]methyl}-4- [(2S)-3,3,3-trifluoro-2-hydroxypropyl]-2,4-dihydro-3H-l,2,4-triazol-3-one (Example 6A, 150 mg, 300 muiotaetaomicron) in ethanol (600 mu) was treated with D-prolinamide (342 mg, 3.00 mmol) and heated at reflux overnight. The reaction mixture was purified by preparative HPLC (Method 4) affording 137 mg (79 % of th.) of the title compound. LC-MS (Method 2): Rt = 1.03 min; MS (ESIpos): m/z = 578.2 [M+H]+ -NMR (400 MHz, DMSO-d6) delta [ppm]: 8.73 (s, 1H), 8.27-8.00 (m, 2H), 7.80-7.50 (m, 4H), 7.30 (s, 1H), 7.10 (s, 1H), 6.91 (d, 1H), 6.52 (d, 1H), 5.19-4.99 (m, 2H), 4.40-4.20 (br m, 1H), 4.16-3.76 (m, 3H), 2.93-2.66 (m, 2H), 2.11-1.91 (m, 1H), 1.85-1.44 (m, 3H).

The synthetic route of 62937-45-5 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; BAYER AKTIENGESELLSCHAFT; BAYER PHARMA AKTIENGESELLSCHAFT; COLLIN-KROePELIN, Marie-Pierre; KOLKHOF, Peter; NEUBAUER, Thomas; FUeRSTNER, Chantal; POOK, Elisabeth; WITTWER, Matthias, Beat; LUSTIG, Klemens; TINEL, Hanna; LINDNER, Niels; SCHIRMER, Heiko; (449 pag.)WO2019/81307; (2019); A1;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

62937-45-5, D-Prolinamide is a catalyst-ligand compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

Example 7: 1-r(3-(6-Methyl-4-r(3.3.3-trifluoro-2-m(4-fluorophenvnsulfonylU1- methylethv?aminolmethyl’y-2-hvdroxypropy?aminol-1/-/-indazol-1-yl)phenv?carbonyl1- D-prolinamide; lambda/,lambda/-Diisopropylethylamine (0.0644mL) and HATU (29.5mg) were added to a solution of 3-(4-{[2-({ethyl[(4-fluorophenyl)sulfonyl]amino}methyl)-3,3,3-trifluoro-2- hydroxypropyl]amino}-6-methyl-1/-/-indazol-1-yl)benzoic acid (45mg, 0.074mmol) in DMF (1.4mL) and the mixture stirred at room temperature under for 10 min. D- Prolinamide (21.1 mg) was then added and the mixture stirred at room temperature overnight. More D-prolinamide was added and the mixture stirred for a further 24 hours and then diluted slightly with methanol and purified by mass directed autopreparation (System B). Product containing fractions were combined and partitioned between dichloromethane and saturated aqueous sodium bicarbonate. The aqueous phase was re-extracted with dichloromethane and the combined organic extracts were washed successively with water and brine, dried through a hydrophobic frit and evaporated to give the title compound (22.2mg). LCMS: tRET = 3.38 min; MH+ = 70519mg of this mixture of diastereomers was resolved by chiral HPLC on a 2 x 25cm Chiralpak AD column eluted with heptane : iso-propanol 1 : 1 with a flow rate of 15 mL/min to provide Example 7-A (diastereomer A, 6.5mg) and Example 7-B (diastereomer B, 7.5mg).Example 7-A (diastereomer A): Analytical chiral HPLC (25 x 0.46 cm Chiralpak AD column, heptane : iso-propanol 1 : 1 eluting at 1 mL/min): tREtau = 8.6 min LCMS: tRET = 3.41 min; MH+ = 705Example 7-B (diastereomer B): Analytical chiral HPLC (25 x 0.46 cm Chiralpak AD column, heptane : iso-propanol 1 : 1 eluting at 1 mL/min): tREtau = 11.6 min LCMS: tRET = 3.59 min; MH+ = 705, 62937-45-5

As the paragraph descriping shows that 62937-45-5 is playing an increasingly important role.

Reference£º
Patent; GLAXO GROUP LIMITED; WO2009/50218; (2009); A1;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

103505-54-0, [2,2′-Bipyridine]-6,6′(1H,1’H)-dione is a catalyst-ligand compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

As shown in Synthesis Scheme 1-a, to a dicationic Cp * iridium-aco complex (407.8 mg, 0.60 mmol) was added 6,6′-dihydroxy-2,2′-bipyridine ligand (113.8 mg, 0 , 60 mmol) was allowed to act in an aqueous solvent (12 mL) to obtain a complex A (yield 93%). Subsequently, neutral iridium complex 1 was obtained by allowing sodium t-butoxide (211.4 mg, 2.2 mmol) to react with complex A (915.0 mg, 1.1 mmol) in an aqueous solvent (30 mL) (Yield 84%)., 103505-54-0

The synthetic route of 103505-54-0 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; KANTO CHEM CO INC; YAMAGUCHI, RYOHEI; FUJITA, KENICHI; (38 pag.)JP2015/83544; (2015); A;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

62937-45-5, D-Prolinamide is a catalyst-ligand compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

62937-45-5, Example 53(fi)-1 -[5-(4-{(S)-1 -[(S)-6-(2-Hvdroxy-2-methyl-DroDyl)-2-oxo-6-Dhenyl-[1 .3loxazinan-3-yll- ethyl)-phenyl)-pyridin-2-yl1-pyrrolidine-2-carboxylic acid amide; A mixture of 3-{(S)-1 -[4-(6-fluoro-pyridin-3-yl)-phenyl]-ethyl}-(S)-6-(2-hydroxy-2-methyl- propyl)-6-phenyl-[1 ,3]oxazinan-2-one (165 mg), potassium carbonate (76 mg), D-prolinamide (125 mg), and dimethyl sulfoxide (2 ml_) was stirred at 100 ‘ overnight. After cooling to room temperature, aqueous NaHC03 solution was added and the resulting mixture was extracted with dichloromethane. The combined extracts were concentrated and the residue was purified by HPLC on reversed phase (water/methanol) to give the title compound. Yield: 85 mg (43% of theory); Mass spectrum (ESI+): m/z = 543 [M+H]+.

The synthetic route of 62937-45-5 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; VITAE PHARMACEUTICALS, INC.; BOEHRINGER INGELHEIM INTERNATIONAL GMBH; LEFTHERIS, Katerina; ZHUANG, Linghang; TICE, Colin, M.; SINGH, Suresh, B.; YE, Yuanjie; XU, Zhenrong; HIMMELSBACH, Frank; ECKHARDT, Matthias; WO2011/159760; (2011); A1;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

62937-45-5,62937-45-5, D-Prolinamide is a catalyst-ligand compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

A solution of N((5-(5-(difluoromethyl)- 1,3 ,4-oxadiazol-2-yl)pyridin-2-yl)methyl)-N-phenylethenesulfonamide (0.100 g, 0.255 mmol), D-(-)-Prolinamide (0.058 g, 0.5 10 mmol) and Diisopropylethylamine (0.176 mL, 1.019 mmol) in dichioromethane (5 mL) was stirred at the room temperature for 24 hr. Then, water was added to the reaction mixture, followed by extraction with dichloromethane. The organic layer was washed with aqueous saturated sodium chloride solution, dried with anhydrous MgSO4, filtered, and concentrated in vacuo. The residue was chromatographed (Si02, 12 g cartridge; methanol / dichloromethane = 5 % to 10 %) to give(R)- 1 -(2-(N-((5-(5-(difluoromethyl)- 1,3 ,4-oxadiazol-2-yl)pyridin-2-yl)methyl)-N-phen ylsulfamoyl)ethyl)pyrrolidine-2-carboxamide as white solid (0.045 g, 34.9 %).?H NMR(400 MHz, CD3OD): oe 9.17 (dd, 1 H, J= 2.2, 0.8 Hz), 8.43 (dd, 1 H, J=8.3, 2.3 Hz), 7.76 (dd, 1 H, J = 8.2, 0.8 Hz), 7.55 – 7.44 (m, 2 H), 7.46 – 7.35 (m, 1 H),7.40 – 7.19 (m, 3 H), 5.17 (s, 2 H), 3.63 – 3.46 (m, 2 H), 3.32 – 2.76 (m, 3 H), 2.65 (q, 1H, J= 7.3 Hz), 2.45 -2.28 (m, 1 H), 2.30-2.12 (m, 1 H), 1.92- 1.71 (m, 3 H); LRMS(ES) mlz 507.3 (M¡Â+1).

The synthetic route of 62937-45-5 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; CHONG KUN DANG PHARMACEUTICAL CORP.; LEE, Jaekwang; HAN, Younghue; KIM, Yuntae; CHOI, Daekyu; MIN, Jaeki; BAE, Miseon; YANG, Hyunmo; KIM, Dohoon; (644 pag.)WO2017/18803; (2017); A1;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

4730-54-5, 1,4,7-Triazacyclononane is a catalyst-ligand compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated,4730-54-5

To a25 mL round bottom flask was added 157.5 mg(1.219 mmol)TACN (1,4,7-triazacyclononane), 3.4 equivalents of 2-bromoacetamide (565.7 mg, 4.100 mmol), and 12 mL ethanol. 3.5 mL triethylamine was added dropwise over several minutes until the solution turned cloudy and persisted, then the mixture was refluxed for 3 hours. After cooling, the mixture was decanted to remove most of the liquid, then 20 mL of warm80% ethanol/20 % water was added to yield a slightly opaque white solution resembling nonfat milk. The volume was slightly reduced under vacuum on a Schlenk line, then placed in the freezer for 3 days to recrystallize. After allowing white crystals to form, the solvent was removed by decanting and further dried under vacuum on the Schlenk line (90 % yield).ESI-MS: m/z = 301.3 (100 %), 302.3 (20 %) [M + H]+; 323.3 (25 %) [M + Na]+. 500 MHz?H NMR spectrum, D20 + DC1: ppm = 3.96 (s, 6H, amide CH2); 3.44 (s, 12H, ring CH2). 75MHz 13C NMR spectrum, D20: ppm = 173.64 (amide CO), 56.75 (amide CH2), 49.30 (ring CH2).

4730-54-5 1,4,7-Triazacyclononane 188318, acatalyst-ligand compound, is more and more widely used in various fields.

Reference£º
Patent; THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK UNIVERSITY AT BUFFALO; HEALTH RESEARCH, INC.; MORROW, Janet, R.; TSITOVICH, Pavel, B.; DORAZIO, Sarina, J.; OLATUNDE, Abiola, O.; SNYDER, Eric, M.; SPERNYAK, Joseph, A.; BURNS, Patrick; BOND, Christopher, J.; WO2015/38943; (2015); A1;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.294-90-6,1,4,7,10-Tetraazacyclododecane,as a common compound, the synthetic route is as follows.

1-(N-acetyl-aza-15-crown-5)-1,4,7,10-tetraazacyclododecane (1b). 260.0 mg (0.88 mmol) 1a dissolved in 10 mL anhyrous acetonitrile was added dropwise to a mixture of cyclen (378.5 mg, 2.20 mmol, 2.5 equiv.), potassium carbonate (5.0 equivs) in 40 mL warm anhydrous acetonitrile under N2 atmosphere for approximately half an hour. The mixture was then stirred at 65-70 C. for about 12 h. The solution was filtered under reduced pressure and the filtrate was evaporated to leave a crude oil that was purified by column chromatography on aluminium oxide with DCM_MeOH=100:5 as an eluent. The product 2 was isolated as a colorless oil (326.6 mg, 0.76 mmol, 86%). 1H NMR (400 MHz, CDCl3): delta 3.74-3.66 (2H, t, J=6.2 Hz), 3.59-3.47 (14H, m), 3.46-3.36 (6H, m), 2.95-2.93 (1H, br), 2.84-2.81 (1H, br), 2.79-2.70 (7H, m), 2.62-2.54 (7H, m); 13C NMR (100 MHz, CDCl3): delta 171.3 (C), 71.4 (CH2), 70.5 (CH2), 70.2 (CH2), 69.9 (3¡ÁCH2), 69.7 (CH2), 69.3 (CH2), 56.9 (CH2), 56.0 (CH2), 52.3 (CH2), 52.1 (CH2), 49.6 (CH2), 49.4 (CH2), 48.5 (CH2), 48.0 (CH2), 46.7 (CH2), 45.6 (CH2), 45.3 (CH2); ESI-MS m/z 432.4 (M+H)+; HRFAB-MS m/z 432.3193 (M+H)+[Calcd. for C20H42N5O5 (M+H)+, 432.3186].

294-90-6, The synthetic route of 294-90-6 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; Wong, Wing-Tak; Li, Cong; US2006/57071; (2006); A1;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI

62937-45-5,With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.62937-45-5,D-Prolinamide,as a common compound, the synthetic route is as follows.

Methyl /so-butyl ketone (MIBK; 3.87 ml/g of mandelic acid) was added to the mandelic acid (1 eq.) at ambient temperature. Stirring was started and the solution was heated to 80C. A solution of D-prolinamide (0.5 eq.) in MIBK (0.43 ml/g of mandelic acid) and water (3 molar equivalent/mandelic acid) was added and crystallisation started soon after. After half an hour additional MIBK (3.87 ml/g of mandelic acid) was added and then a solution of D-prolinamide (0.7 eq.) in MIBK (0.43 ml/g of mandelic acid) and water (3 molar equivalent/mandelic acid). The suspension was stirred at 100C for 22 hours. The suspension was cooled to O0C over 2.25 hours. The substance was isolated by filtration, washed with MIBK and then dried (crude yield 84.9 %). The ee of the crude D-prolinamide salt of the (i?)-enantiomer of the mandelic acid was 94.32%. If the optical purity and the assay of the salt are not satisfactory, a series of slurry wash experiments in a number of solvents has shown that both the optical purity and the assay (physical content purity) can be improved. A slurry wash in acetone, for example, gave the (R)- mandelic acid.D-prolinamide salt with 99.1% ee. The yield including the slurry wash was 81.8%. With 2-butanone (MEK) as solvent for the slurry wash, the (i?)-mandelic acid.D- prolinamide salt was obtained with 96.0% ee in 83.9% yield. Other solvents or solvent mixtures which can be used for the slurry wash are MIBK with 20 % w/w H2O, acetonitrile, and 2- propanol.

As the paragraph descriping shows that 62937-45-5 is playing an increasingly important role.

Reference£º
Patent; ASTRAZENECA AB; ASTRAZENECA UK LIMITED; WO2006/125964; (2006); A1;,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI